These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38487336)

  • 1. Rapid response of thyroid eye disease, peripheral edema, and acropathy to teprotumumab infusion.
    Kelly DA; Turbin RE
    Am J Ophthalmol Case Rep; 2024 Jun; 34():102031. PubMed ID: 38487336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease.
    Xin Y; Xu F; Gao Y; Bhatt N; Chamberlain J; Sile S; Hammel S; Holt RJ; Ramanathan S
    Clin Pharmacokinet; 2021 Aug; 60(8):1029-1040. PubMed ID: 33768488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid dermopathy responds to teprotumumab therapy.
    Crespo-Trevino R; Schiffman J; Ugradar S; Cockerham K; Douglas R; de Leon-Garza D; Tang R
    Endocrinol Diabetes Metab Case Rep; 2022 Mar; 2022():. PubMed ID: 35319490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refractory Thyroid Eye Disease Unresponsive to Teprotumumab: A Case Report.
    Singh G; Taylor B; Michalek S
    Cureus; 2023 Nov; 15(11):e48861. PubMed ID: 38111423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Audiology findings in patients with teprotumumab associated otologic symptoms.
    Yu CY; Correa T; Simmons BA; Hansen MR; Shriver EM
    Am J Ophthalmol Case Rep; 2021 Dec; 24():101202. PubMed ID: 34585021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report.
    Ding AS; Mahoney NR; Campbell AA; Creighton FX
    Otol Neurotol; 2022 Feb; 43(2):e148-e152. PubMed ID: 34789694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.
    Ugradar S; Kossler AL; Douglas R; Cockerham K
    J Neuroophthalmol; 2022 Mar; 42(1):26-34. PubMed ID: 35500236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teprotumumab in advanced reactivated thyroid eye disease.
    Cheng OT; Schlachter DM
    Am J Ophthalmol Case Rep; 2022 Jun; 26():101484. PubMed ID: 35321251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teprotumumab in thyroid eye disease.
    Goldberg H; Malik AI
    Saudi J Ophthalmol; 2024; 38(1):29-33. PubMed ID: 38628412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teprotumumab for the treatment of thyroid eye disease.
    Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A
    Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
    Kossler AL; Douglas R; Dosiou C
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early experience with teprotumumab for chronic thyroid eye disease.
    Ozzello DJ; Kikkawa DO; Korn BS
    Am J Ophthalmol Case Rep; 2020 Sep; 19():100744. PubMed ID: 32462101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
    Kahaly GJ; Subramanian PS; Conrad E; Holt RJ; Smith TJ
    Thyroid; 2024 Jun; ():. PubMed ID: 38824618
    [No Abstract]   [Full Text] [Related]  

  • 17. Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease.
    Hoang TD; Nguyen NT; Chou E; Shakir MK
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33972303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease.
    Safo MB; Silkiss RZ
    Am J Ophthalmol Case Rep; 2021 Jun; 22():101069. PubMed ID: 33817409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study.
    Sears CM; Wang Y; Bailey LA; Turbin R; Subramanian PS; Douglas R; Cockerham K; Kossler AL
    Am J Ophthalmol Case Rep; 2021 Sep; 23():101111. PubMed ID: 34113737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
    Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN
    J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.